Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)

The investigators will analyzed proteomes of paired normal lung tissues and pulmonary sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Inclusion Criteria:

• Age ≤ 70 years with histologically proven LCLC
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion Criteria:

• Age ≥ 70
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Patients with pulmonary sarcomatoid carcinoma

There is no plan to make individual participant data (IPD) available to other researchers.